Education
About Us
Working with TipRanks
Follow Us
Embecta Corporation (EMBC)
NASDAQ:EMBC
EMBC Stock Chart & Stats
$10.53
$0.16(0.83%)
At close: 4:00 PM EST
$10.53
$0.16(0.83%)
Day’s Range― - ―
52-Week Range$8.72 - $15.55
Previous CloseN/A
Volume119.84K
Average Volume (3M)922.87K
Market Cap
$526.46M
Enterprise Value$1.74B
Total Cash (Recent Filing)$204.40M
Total Debt (Recent Filing)$1.42B
Price to Earnings (P/E)3.9
Beta1.01
Next Earnings
May 08, 2026EPS Estimate
0.42Next Dividend Ex-DateN/A
Dividend Yield5.03%
Share Statistics
EPS (TTM)0.71
Shares Outstanding59,219,852
10 Day Avg. Volume944,052
30 Day Avg. Volume922,871
Financial Highlights & Ratios
PEG Ratio0.42
Price to Book (P/B)-1.26
Price to Sales (P/S)0.76
P/FCF Ratio4.51
Enterprise Value/Market Cap3.31
Enterprise Value/Revenue1.61
Enterprise Value/Gross Profit2.53
Enterprise Value/Ebitda4.96
Forecast
1Y Price Target
$25.00Price Target Upside137.42% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)2.82
Revenue Forecast (FY)$1.07B
Bulls Say, Bears Say
Bulls Say
Acquisition And Product PlatformAcquisition of Owen Mumford brings the Aidaptus auto-injector platform and complementary pharma services, expanding B2B product offerings and leveraging existing manufacturing scale.
Commercial PartnershipsMultiple pharmaceutical partners planning to co-package pen needles with generic GLP-1 therapies creates a new cross-border product opportunity that could drive meaningful volume growth.
Geographic ExpansionStrong international sales momentum combined with a large revenue base in the United States and the United Kingdom provides geographic diversification that can support revenue and earnings stability.
Bears Say
Leverage And Interest ExpenseThe transaction is expected to increase leverage and raise annual interest payments, creating near-term pressure on cash flow and financial flexibility.
U.S. Pricing PressureLower U.S. pricing driven by customer mix and competition has reduced revenue and pushed guidance toward the low end, risking further margin compression if pricing trends continue.
Embecta Corporation News
EMBC FAQ
What was Embecta Corporation’s price range in the past 12 months?
Embecta Corporation lowest stock price was $8.72 and its highest was $15.55 in the past 12 months.
What is Embecta Corporation’s market cap?
Embecta Corporation’s market cap is $526.46M.
When is Embecta Corporation’s upcoming earnings report date?
Embecta Corporation’s upcoming earnings report date is May 08, 2026 which is in 46 days.
How were Embecta Corporation’s earnings last quarter?
Embecta Corporation released its earnings results on Feb 05, 2026. The company reported $0.71 earnings per share for the quarter, beating the consensus estimate of $0.671 by $0.039.
Is Embecta Corporation overvalued?
According to Wall Street analysts Embecta Corporation’s price is currently Undervalued.
Does Embecta Corporation pay dividends?
Embecta Corporation pays a Quarterly dividend of $0.15 which represents an annual dividend yield of 5.03%. See more information on Embecta Corporation dividends here
What is Embecta Corporation’s EPS estimate?
Embecta Corporation’s EPS estimate is 0.42.
How many shares outstanding does Embecta Corporation have?
Embecta Corporation has 59,219,852 shares outstanding.
What happened to Embecta Corporation’s price movement after its last earnings report?
Embecta Corporation reported an EPS of $0.71 in its last earnings report, beating expectations of $0.671. Following the earnings report the stock price went down -7.75%.
Which hedge fund is a major shareholder of Embecta Corporation?
Currently, no hedge funds are holding shares in EMBC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Embecta Corporation Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$25.00 (137.42% Upside)
$25.00 (137.42% Upside)
Blogger Sentiment
Neutral
EMBC Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 279.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 4.6%
Last 30 Days ▲ 4.6%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.27%
12-Months-Change
Fundamentals
Return on Equity
-20.90%
Trailing 12-Months
Asset Growth
-7.46%
Trailing 12-Months
Company Description
Embecta Corporation
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, Dickinson and Company as of April 1, 2022.
EMBC Company Deck
EMBC Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed mixed near-term operational challenges—notably U.S. pricing and volume headwinds, pen needle declines, China weakness and a meaningful drop in contract manufacturing—balanced against several strategic and financial positives: strong international growth (EMEA and Latin America), category growth in syringes and safety products, meaningful progress on brand transition and Medicare Part D access, tangible GLP-1 commercial traction with >30 partners and executed purchase orders, continued deleveraging (net leverage ~2.8x) and improved GAAP profitability metrics. Management reaffirmed guidance but signaled being nearer the low end due to U.S. pressures. Overall, the call emphasized execution on multi-year strategic initiatives and financial stability, while acknowledging near-term headwinds that temper upside.View all EMBC earnings summariesEMBC Stock 12 Month Forecast
Average Price Target
$25.00
▲(137.42% Upside)
Technical Analysis
―
Pacira Pharmaceuticals
―
SIGA Technologies
―
Collegium Pharmaceutical
―
Organogenesis Holdings
―
Ownership Overview
3.34% Insiders
29.43% Mutual Funds
25.99% Other Institutional Investors
17.35% Public Companies and
Individual Investors